Melanotan I

Melanotan I (afamelanotide) selectively targets MC1R receptors, producing pigmentation effects only. Melanotan II is a non-selective melanocortin agonist that activates MC1R, MC3R, MC4R, and MC5R, causing pigmentation plus sexual arousal, appetite suppression, and other effects. MT-I has a cleaner safety profile because it avoids off-target receptor activation.

Yes. Afamelanotide (branded as Scenesse) received FDA approval in October 2019 for the treatment of erythropoietic protoporphyria (EPP), a rare genetic disorder causing extreme sun sensitivity. It is the only FDA-approved melanocortin receptor agonist for a dermatological indication.

Scenesse is only FDA-approved for EPP, not cosmetic tanning. While MT-I does increase skin pigmentation, using it off-label for tanning is not approved and research peptide versions are not pharmaceutical grade. The clinical trials focused on photoprotection in EPP patients, not cosmetic outcomes.

No. Melanotan I selectively targets MC1R and does not significantly activate MC4R, the receptor responsible for the sexual function effects seen with Melanotan II. This selective targeting is one of the main advantages of MT-I over MT-II.

The FDA-approved version (Scenesse) is a subcutaneous implant placed by a healthcare provider every 2 months. Research peptide versions come as lyophilized powder for subcutaneous injection, but these are not FDA-approved formulations.

Current evidence does not show an increased melanoma risk with afamelanotide. The selective MC1R activation actually promotes eumelanin production, which is the protective form of melanin. However, any compound that stimulates melanocytes warrants monitoring. Regular dermatological exams are recommended.

Pigmentation from MT-I persists for several weeks after the implant is depleted because melanin is deposited in keratinocytes and remains until those cells naturally shed through epidermal turnover. The effect gradually fades over 4-8 weeks without continued treatment.

The most common side effects are mild nausea, headache, and injection site reactions. Darkening of existing moles and freckles can occur. The side effect profile is significantly milder than Melanotan II because MT-I does not activate the receptors responsible for sexual effects, blood pressure changes, or severe nausea.

Scenesse (afamelanotide) is a legal, FDA-approved prescription medication for EPP. Research-grade Melanotan I peptide is legal to purchase for research purposes in most jurisdictions but is not approved for human cosmetic use.

Scenesse (the FDA-approved implant) is a specialty medication with a high cost, typically covered by insurance for EPP patients. Research peptide versions are significantly less expensive but are not pharmaceutical grade and lack FDA oversight.

Preliminary research suggests melanocortin agonists may have potential for repigmentation in vitiligo, but this is not an approved indication. Clinical trials are ongoing. Consult a dermatologist for current treatment options.

EPP is a rare genetic disorder where the body produces excess protoporphyrin IX, causing extreme sensitivity to sunlight. Even brief sun exposure causes severe burning pain, swelling, and scarring. Scenesse (afamelanotide) increases melanin to provide a protective barrier against this phototoxic reaction.